Questcor Pharmaceuticals is seeing its shares down more than 40% at $27.00 and its 52-week trading range is $24.14 to $58.91.
It was just yesterday that Oppenheimer & Co. raised its price target to $69 from $59 while maintaining an Outperform rating on the understanding that Questcor will get more revenue from H.P. Acthar gel. The timing of that research call is perhaps very unlucky, but that can happen in these situations.
Questcor is no stranger to big drops, but this by far the worst seen in a day. Earlier this year it saw its shares drop from $55 to $35 in a fairly short period of time.
Stay tuned and look for a press release from Questcor shortly.
JON C. OGG
Take This Retirement Quiz To Get Matched With An Advisor Now (Sponsored)
Are you ready for retirement? Planning for retirement can be overwhelming, that’s why it could be a good idea to speak to a fiduciary financial advisor about your goals today.
Start by taking this retirement quiz right here from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes. Smart Asset is now matching over 50,000 people a month.
Click here now to get started.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.